Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.47% | 127.60% | 136.35% | 123.76% | 76.72% |
| Total Depreciation and Amortization | -11.67% | -11.95% | -12.54% | -11.14% | -10.22% |
| Total Amortization of Deferred Charges | 232.14% | 32.43% | -13.76% | -99.14% | -89.71% |
| Total Other Non-Cash Items | -86.33% | -21.62% | -51.52% | -109.46% | -86.05% |
| Change in Net Operating Assets | -34.07% | -125.25% | -187.50% | -119.68% | 151.25% |
| Cash from Operations | 34.42% | 190.63% | -92.38% | 119.48% | 229.68% |
| Capital Expenditure | 19.75% | 39.74% | 64.42% | 64.47% | 66.81% |
| Sale of Property, Plant, and Equipment | -99.78% | 383.54% | 406.58% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -100.00% | -- | -59.22% |
| Other Investing Activities | -63.64% | 50.00% | -- | 1,290.48% | 973.02% |
| Cash from Investing | -96.16% | -44.57% | 19.60% | 575.49% | -9.74% |
| Total Debt Issued | -- | -- | -100.00% | 157.65% | 234.29% |
| Total Debt Repaid | 76.24% | 76.68% | 98.62% | -222.15% | 16.03% |
| Issuance of Common Stock | -77.06% | -79.63% | -83.18% | 678.57% | 6.86% |
| Repurchase of Common Stock | -2,792.31% | -2,091.67% | -1,610.00% | -925.00% | -62.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 179.66% | -- |
| Cash from Financing | 36.13% | 28.11% | 88.05% | -284.74% | 52.30% |
| Foreign Exchange rate Adjustments | 214.29% | -- | 106.67% | 175.00% | 30.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.21% | 1,796.72% | 35.28% | 1,236.36% | 121.01% |